The lab vs. leadership paradox: Making decisions without all the answers

Few industries are as comfortable with failure as pharma. Scientists routinely develop hypotheses, run experiments, analyse results, and refine their thinking in response to what emerges. Many of these experiments don’t produce the intended breakthrough, yet they still generate insight, narrow possibilities, and improve the quality of the next round of decisions.

Failure in this context is absorbed into the process of learning as something expected and useful. So why is it that this pattern of thinking doesn’t always travel from the lab to leadership?

Decision-making often becomes slower as more stakeholders are brought into alignment and consensus begins to take precedence over direction. Leaders can find themselves waiting for additional information before committing to a course of action, particularly when the stakes feel high or the implications are uncertain. Over time, this can create a culture where avoiding the risk of getting things wrong begins to shape behaviour as much as the ambition to move things forward.

This creates a paradox. Organisations that depend on experimentation to discover and develop life-changing medicines can find themselves applying a very different set of assumptions when it comes to leadership and strategy.

That tension matters more than ever because the environment pharmaceutical leaders are operating in has changed fundamentally.

From VUCA to BANI

For years, leaders have been operating in an external environment often described as VUCA: volatile, uncertain, complex, and ambiguous. Today, even that framework feels insufficient. Increasingly, we are operating in what is being described as a BANI world: brittle, anxious, non-linear, and incomprehensible.

Healthcare systems are under sustained pressure, regulatory environments continue to evolve, and scientific innovation is accelerating across multiple therapeutic areas. At the same time, AI is reshaping parts of the value chain, geopolitical instability is influencing supply chains, and commercial models are having to adapt to changing patient and payer expectations.

In this context, leaders often find themselves reaching for greater certainty before making commitments. The difficulty is that certainty rarely arrives in a form that feels complete enough to act on, and waiting for it can gradually become a way of slowing decisions without explicitly choosing to do so.

The lessons from the pandemic

The pandemic provided a clear demonstration of how much pace is possible within when the conditions demand it. Across the pharma sector, collaboration increased, regulatory pathways were adapted, and decisions that would previously have taken extended periods were made in compressed timeframes. Established assumptions about sequencing, approval cycles, and acceptable timelines were temporarily rewritten in response to necessity.

But once the immediate pressure of the crisis eased, the system reverted. This raises an important question for leaders. If pace was possible under those conditions, what prevents it from being sustained when the external environment continues to demand speed, responsiveness, and adaptability?

Learning from the scientist's mindset

Within scientific environments, progress is understood as cumulative rather than linear. An experiment may confirm a hypothesis, challenge it, or fail to produce a clear result, yet each outcome still contributes to the broader understanding of the system being studied. The emphasis is placed on what can be learned and how that learning informs the next iteration.

In leadership contexts, strategic decisions are often held to a different standard of judgement. When initiatives don’t deliver the expected outcome, the focus can shift quickly towards attribution, accountability, and reputational impact. This naturally increases the perceived cost of being wrong.

As that cost perception rises, behaviour adjusts. Decisions take longer to surface, options are narrowed earlier in the process, and organisations can become more selective about which risks feel acceptable. Over time, this can reduce momentum in ways that are not always immediately visible.

An organisation may remain active and fully operational, while the rate at which it generates meaningful progress begins to slow. There is an irony in this dynamic. Industries that rely on experimentation to drive scientific breakthroughs can become more cautious when applying experimentation to the decisions that shape direction, investment, and strategy.

In environments defined by complexity, there is value in treating strategy as something that evolves through structured learning rather than something that must be fully resolved in advance.

The danger of passive leadership

One consequence of prolonged uncertainty is the gradual emergence of leadership cultures that prioritise stability and alignment over challenge and momentum.

These patterns tend to form when difficult conversations are deferred, or when leaders become cautious about committing to positions without full agreement. As this becomes more common, organisations can develop a kind of operational comfort. Reporting structures remain intact and activity levels can still stay high. However, the pace of meaningful progress will slow over time.

Difficult issues remain unresolved for longer, and important decisions can drift rather than being made explicitly.

In an industry where scientific and technological change continues to accelerate, this creates a growing gap between the pace of the environment and the pace of organisational response.

The emerging leadership challenge

Leading in a BANI environment doesn’t require abandoning rigour. Nor does it suggest that faster decision-making is always better decision-making. What it does surface, increasingly, is a tension between the level of certainty leaders would ideally like to have and the level of certainty that is realistically available at the point decisions need to be made.

In practice, this often shows up as a preference for additional validation, extended alignment cycles, or further analysis before committing to direction. These are understandable responses in an industry where the stakes are high and the consequences of error can be significant.

At the same time, many of the challenges shaping the pharmaceutical landscape don’t wait for full resolution before moving forward. Within this context, a growing number of leadership teams are grappling with how to maintain both scientific rigour and organisational momentum when neither full certainty nor complete consensus is readily available.

The challenge is not simply about making faster decisions. It’s about finding ways to act responsibly with incomplete information, and to refine direction as understanding develops.

If you’d like to learn more about leading with conviction in an increasingly BANI world, get in touch.